• norsk
    • English
  • English 
    • norsk
    • English
  • Login
View Item 
  •   Home
  • Norges Handelshøyskole
  • Department of Business and Management Science
  • Articles (FOR)
  • View Item
  •   Home
  • Norges Handelshøyskole
  • Department of Business and Management Science
  • Articles (FOR)
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

The cost of multiple sclerosis in Norway

Svendsen, Bjørn; Myhr, Kjell-Morten; Nyland, Harald Inge; Aarseth, Jan Harald
Journal article, Peer reviewed
Thumbnail
View/Open
costofmultiplesclerosis_svendsen.pdf (220.6Kb)
URI
http://hdl.handle.net/11250/163544
Date
2010
Metadata
Show full item record
Collections
  • Articles (FOR) [100]
Original version
The European Journal of Health Economics, 2012, 13:81–91   10.1007/s10198-010-0286-7
Abstract
Health economic aspects have been increasingly

important during introduction of new treatments for

multiple sclerosis. As a partial response for Norway, a costof-

illness study was carried out to estimate the yearly cost

of the illness to society and relate costs and patients’

quality of life to illness severity. Estimated cost to society

was Euro 439 million in 2002 exclusive of the cost of

reduced quality of life. The cost per patient was close to

Euro 65,000. Account taken of methodological differences,

the results compare to results for Sweden, Norway’s closest

neighboring country. The illness reduced patients’ quality

of life with 0.26. More patients were early retired because

of their MS in Norway than in any of nine other European

countries comprised by a recent European study, illustrating

a liberal practice in Norway. The Norwegian cost of

unpaid assistance was almost identical to the Swedish cost

that was the lowest found across the countries in the

European study. When related to illness severity, the cost

per patient increased, and the patients’ experienced quality

of life decreased with increasing EDSS levels in line with

what has been found for other countries. Cost-of-MS

studies have been carried out for a number of countries.

Together they contribute to our understanding of the economic

consequences of multiple sclerosis and, if their

results are related to illness severity, also provide valuable

information for further economic analyses of treatment and

medication. Our study adds to this.
Publisher
Springer
Journal
The European Journal of Health Economics

Contact Us | Send Feedback

Privacy policy
DSpace software copyright © 2002-2019  DuraSpace

Service from  Unit
 

 

Browse

ArchiveCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsDocument TypesJournalsThis CollectionBy Issue DateAuthorsTitlesSubjectsDocument TypesJournals

My Account

Login

Statistics

View Usage Statistics

Contact Us | Send Feedback

Privacy policy
DSpace software copyright © 2002-2019  DuraSpace

Service from  Unit